JOHNSON & JOHNSON
Government Contracts & Awards
NORTH EAST SOUTH WEST HEALTHCARE SOLUTIONS, LLC: $16.5M Department of Homeland Security Contract
$16,465,998Proprietary Tech & Patents
WAVEFRONT SENSOR-BASED SYSTEMS FOR CHARACTERIZING OPTICAL ZONE DIAMETER OF AN OPHTHALMIC DEVICE AND RELATED METHODS
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy.1,2
Johnson & Johnson: What the Street’s Reaction to OTTAVA Actually Reveals About the Stock
Key TakeawaysJohnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7. 89 billion to $8.
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now
Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson vs. AbbVie valuation: JNJâs P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the full analysis here.
Johnson & Johnson Announces Data From Phase 3 MajesTEC-3 Trial Demonstrates Disease Control, Survival With TECVAYLI Plus DARZALEX FASPRO To Treat Relapsed Or Refractory Multiple Myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI®
What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For Shareholders
Johnson & Johnson recently reported positive topline Phase 3 results for CAPLYTA (lumateperone) in adults with bipolar I disorder experiencing manic episodes, showing rapid and statistically significant symptom reduction versus placebo, while also highlighting progress across its broader neuropsychiatry portfolio. The data suggest CAPLYTA could potentially treat both depressive and acute manic episodes in bipolar I disorder, meaningfully broadening its clinical role if future regulatory...
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?
Johnson & Johnson (NYSE: JNJ) received FDA approval for ICOTYDE (icotrokinra) to treat moderate to severe plaque psoriasis in the U.S. ICOTYDE targets the IL-23 receptor and is in Phase III clinical trials for a potential psoriatic arthritis indication. The new therapy extends Johnson & Johnson's immunology pipeline beyond oncology and MedTech into chronic inflammatory skin and joint conditions. The ICOTYDE psoriasis approval and psoriatic arthritis Phase III program deserves weighing...
Congressional Trades in $JNJ
Insider Trades (Form 4)
Pinto Daniel E
Woods Eugene A.
HEWSON MARILLYN A
Schmid Timothy
Duato Joaquin
Forminard Elizabeth
Broadhurst Vanessa
Woods Eugene A.
Key People
HEWSON MARILLYN A
Director
Pinto Daniel E
Director
Schmid Timothy
EVP, WW Chair, MedTech
Forminard Elizabeth
EVP, Chief Legal Officer
Duato Joaquin
CEO and Chairman of the Board
Broadhurst Vanessa
EVP, Global Corp Affairs
Woods Eugene A
Director
Political Giving
$387,000 given to 59 candidates across 221 disclosed contributions (FEC Schedule A).
Scott H. Peters
Earl Leroy Carter
Katherine M. Clark
August Lee Pfluger
Gus M. Bilirakis
Bradley S. Schneider
Thomas H. Kean
John Rutherford
Suzan K. DelBene
Kevin Hern
Josh Gottheimer
Terri A. Sewell
Diana Harshbarger
Darin McKay LaHood
Jake Auchincloss
Adrian Smith
Blake Moore
Bill Hagerty
Darrell E. Issa
Susan M. Collins
+ 39 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro